Search

everythinglearnresearchcommunity

for

Search:↓

People with androgenetic alopecia, both men and women, are more likely to develop heart diseases in the future.

Women with androgenetic alopecia have normal levels of most blood steroids and binding proteins, but higher dehydroepiandrosterone. Some also have low "sex hormone-binding globulin" and "corticosteroide-binding globulin" capacity, and high "free androgen index" and "free cortisol index". Diane treatment can normalize these levels and improve hair conditions.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Too much androgen can cause hair loss; finasteride may help.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Finasteride safely reduces excessive hair growth in women.

Women with PCOS are at high risk of glucose metabolism issues and heart diseases, especially if overweight, highlighting the need for early intervention.

Testosterone can cause acne and male-pattern baldness, affects hair growth in men and women, and makes male skin more sensitive.

Androgens, like DHT, affect hair growth and treatments like finasteride may help.

A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.

Clinical signs of excess male hormones and actual hormone levels in the blood do not always match in women with polycystic ovary syndrome.

The symptoms described align more with Haberland syndrome, not Delleman-Oorthuys syndrome.

Taking biotin can lead to incorrect low results in free testosterone tests.

Women with PCOS have higher levels of certain androgens, which are good at predicting excess hair growth.

A postmenopausal woman's excessive hair growth and hair loss were due to a non-cancerous ovarian condition, treated successfully with surgery.

The document concludes that more research is needed to include new treatments in guidelines for Polycystic Ovary Syndrome (PCOS).

Free fatty acids may increase androgen production, potentially contributing to polycystic ovary syndrome.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

Exposure to too much androgen before birth might cause polycystic ovary syndrome later in life.

Women with PCOS have overall higher body fat, not abnormal fat placement, and more insulin resistance.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

South Asian women with PCOS are more likely to have metabolic issues and central obesity, and simple measures like waist size and blood pressure can help identify these risks early.

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

Metformin improves hair growth and menstrual frequency in women with PCOS and hirsutism.

New treatments for male hypogonadism are effective and should be personalized.

Certain medications including flutamide, spironolactone, and others effectively reduce excessive hair growth in women, especially when combined with lifestyle changes.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Women with PCOS have higher androgen levels that decrease with age but are still higher than in women without PCOS.